Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice

Area of Science:

• Pharmacology
• Metabolic Diseases
• Natural Products

Background:

• Osthole, derived from traditional herbs, is explored for treating metabolic syndromes.
• Diabetes mellitus remains a significant global health challenge requiring novel therapeutic strategies.

Purpose of the Study:

• To investigate the hypoglycemic effects of osthole in diabetic db/db mice.
• To elucidate the underlying molecular mechanisms of osthole's action in vitro and in vivo.

Main Methods:

• In vitro assays, including transition transfection assays, were used to assess osthole's effects on PPARalpha and PPARgamma.
• Cellular experiments evaluated the activation of AMP-activated protein kinase (AMPK) and acetyl CoA carboxylase.
• Diabetic db/db mice were treated with osthole via different routes to measure blood glucose, insulin, and lipid levels.

Main Results:

• Osthole dose-dependently activated both PPARalpha and PPARgamma, increasing the expression of their target genes.
• Osthole enhanced the phosphorylation of AMPK and acetyl CoA carboxylase.
• In vivo, osthole significantly reduced blood glucose levels in diabetic mice without altering insulin or lipid profiles.

Conclusions:

• Osthole acts as a dual PPARalpha/gamma activator and activates the AMPK pathway.
• Unlike traditional insulin sensitizers, osthole alleviates hyperglycemia without affecting insulin or lipid levels.
• Osthole demonstrates potential as a novel therapeutic agent for managing diabetes mellitus.